Parexel Expands Early Phase Drug Development Capabilities
PAREXEL International Corporation (NASDAQ:PRXL), a global biopharmaceutical services provider, announced that the Company has expanded its early phase drug development capabilities to provide biopharmaceutical companies with dedicated support for Proof of Concept studies.
Boston, MA, September 23, 2008 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has expanded its early phase drug development capabilities to provide biopharmaceutical companies with dedicated support for Proof of Concept studies. PAREXEL's new Proof of Concept unit integrates expertise and capabilities in regulatory strategies, drug development, and clinical pharmacology. Proof of Concept studies are mainly conducted in targeted patient populations and are designed to demonstrate early signals of a product's efficacy. The goal of these studies is to help clients avoid costly late stage clinical development failures by making better and faster go/no-go decisions
"As the biopharmaceutical industry explores new development paradigms to bring safe and effective treatments to market more efficiently, companies are conducting a growing number of complex and rigorous Proof of Concept
studies. Providing clients with integrated, early phase development strategies and expertise gives them the ability to support early identification and selection of the most promising compounds,” said Herman Scholtz, M.D., Corporate Vice President, Early Drug Development, PAREXEL.
PAREXEL's dedicated team of experts provides clients with the required scientific, therapeutic, and regulatory expertise to design and implement Proof of Concept studies for new drug entities across a broad range of therapeutic indications. This team offers customized solutions including the appropriate use of biomarkers and adaptive trial designs. Adaptive designs are supported by specialized biostatistical expertise and eClinical technology capabilities. Relevant technologies include Interactive Voice and Web Response Systems (IVRS/IWRS) to randomize patients and track drug inventory as well as electronic data capture to provide rapid access to study data.
To accelerate patient recruitment, the Proof of Concept service offering provides PAREXEL SuperSitesSM capabilities in combination with a broad, global network of investigator and academic sites. PAREXEL SuperSites solutions leverage PAREXEL's hospital-based Clinical Pharmacology Research Units to provide high patient enrollment potential, drawing on dedicated recruitment specialists and relationships with local, hospital-based
physicians as well as using on-site call centers and database capabilities. This allows for a high number of patients to be recruited at these units in a shorter time frame, reducing the overall number of investigator sites, and ultimately decreasing time and cost.
For more information about PAREXEL's early phase development capabilities, visit: http://www.parexel.com/early_phase.html.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
